Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20796131 | 0.84 | MEN1 (0.74) | GAACYP1A2MAPTMEN1KMT2A | |
| SCHEMBL3943376 | 0.82 | MEN1 (0.62) | GAACYP1A2MAPTMEN1KMT2A | |
| SCHEMBL18469873 | 0.81 | KMT2A (0.60) | GAACYP1A2MAPTMEN1KMT2A | |
| SCHEMBL8503181 | 0.81 | KMT2A (0.60) | GAACYP1A2MAPTMEN1KMT2A | |
| SCHEMBL1446574 | 0.81 | KMT2A (0.60) | GAACYP1A2MAPTMEN1KMT2A | |
| SCHEMBL930847 | 0.81 | GAA (0.65) | GAACYP1A2MAPTMEN1KMT2A | |
| SCHEMBL8503182 | 0.81 | KMT2A (0.60) | GAACYP1A2MAPTMEN1KMT2A | |
| SCHEMBL31503950 | 0.81 | KMT2A (0.60) | GAACYP1A2MAPTMEN1KMT2A | |
| SCHEMBL477394 | 0.80 | CYP1A2 (0.73) | GAACYP1A2MAPTMEN1KMT2A | |
| SCHEMBL477396 | 0.80 | CYP1A2 (0.73) | GAACYP1A2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275935-A1 | Estratriene Derivatives | CRYPTOPHARMA PTY LTD (AU) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275935-A1 | Estratriene Derivatives | ESR2, ESRRB, NR3C2 | GAA 4708/4885CYP1A2 265/4885MAPT 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.